Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2021-02-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于公司监事会主席辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the chairman of the supervisory board (监事会主席) of Zhejiang Tailin Biotechnology Co., Ltd. It details the resignation, the legal implications, and the company's plan to elect a new chairman. There is no financial data, no report or presentation, and no mention of voting results or dividends. This is a management-related announcement about a change in a senior supervisory position, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on this personnel change, confirming it is not a full report or other filing type.
2021-02-08 Chinese
关于全资子公司变更经营范围、注册地址并完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding changes in the business scope and registered address of its wholly-owned subsidiary Zhejiang Tailin Medical Engineering Co., Ltd. It details the changes in the business license and registration information. The document does not contain financial statements, management discussion, or any report data. It is a regulatory announcement about corporate registration changes, not a financial report or meeting material. The document length is short (2061 characters) and it is clearly an announcement of a corporate change. Therefore, it fits best under Regulatory Filings (RNS).
2021-02-04 Chinese
关于向不特定对象发行可转换公司债券申请获得深圳证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the acceptance by the Shenzhen Stock Exchange of their application to issue convertible bonds to unspecified investors. It mentions the regulatory review process and the need for approval from the China Securities Regulatory Commission before implementation. The document is short (602 characters) and serves as an update on a capital raising activity, specifically about bond issuance. It is not a full financial report, audit, or earnings release, but an update on financing activity. Therefore, it fits best under Capital/Financing Update (CAP).
2021-02-03 Chinese
最近三年的财务报告及其审计报告以及最近一期的财务报告
Audit Report / Information Classification · 100% confidence The document contains an audit report for Zhejiang Tailin Biotechnology Co., Ltd. for the fiscal year ending December 31, 2017. It includes detailed audit opinions, key audit matters, and extensive financial statements such as consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data indicates this is a standalone audit report rather than a full annual report or a brief announcement. The document length (15,000 characters) and content confirm it is not a mere announcement or certification. Therefore, the document fits the category of an Audit Report / Information (AR).
2021-02-03 Chinese
长城证券股份有限公司关于公司创业板向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled '上市保荐书' which translates to 'Listing Sponsorship Letter' or 'Sponsorship Document for Listing'. It is issued by a securities company (长城证券股份有限公司) regarding the issuance of convertible bonds by 浙江泰林生物技术股份有限公司 for listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). The document contains detailed information about the issuer, the convertible bond issuance, terms of the bonds, risks, financial data, and regulatory compliance. It is a comprehensive document related to the issuance and listing of convertible bonds, including detailed terms and conditions, risk disclosures, and financial data. This type of document is typically a Capital/Financing Update as it relates to fundraising activities and capital structure changes through convertible bond issuance. It is not an annual report, earnings release, or other report types. It is not a mere announcement or a proxy statement. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full detailed document, not just an announcement or summary.
2021-02-03 Chinese
创业板向不特定对象发行可转换公司债券募集说明书
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to "Offering Prospectus" or "Issuance Prospectus" for convertible bonds issued by Zhejiang Tailin Biotechnology Co., Ltd. It contains detailed information about the bond issuance, including company background, risk factors, credit ratings, profit distribution policies, financial data, and legal statements. The document is lengthy (15,000 characters) and includes comprehensive disclosures typical of a capital raising document. It is not an annual or interim report, nor an earnings release or management discussion. It is clearly an issuance prospectus related to a capital market transaction, specifically a convertible bond offering. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-02-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.